Saturday, October 16, 2021 12:36:16 PM
2017 Guidance § III.D.2.a recommends that the following information be included in any request for an EUA:
Description of product and its intended use
Description of the product’s FDA approval status
The need for the product, including whether there are adequate, approved, and available alternatives
Safety and efficacy information:
Required safety information will vary by product and emergency.
It can include, for example, controlled clinical trials, bench testing, and/or clinical experience if the circumstances warrant.
Early discussions with FDA about the required safety and efficacy information are critical.
A discussion of risks and benefits:
A discussion of risks and benefits should include: (a) measures taken to mitigate risk or optimize benefit;
(b) limitations, uncertainty, and data gaps;
(c) contraindications; and
(d) actual and potential threats posed by CBRN agents that may be relevant.
Information on chemistry, manufacturing and controls, and the sites of manufacture, including the current good manufacturing practices (CGMP) status of those sites
Information on the quantity of product on-hand and surge manufacturing capabilities
Information comparable to an FDA-approved package insert or instructions for use;
drafts of fact sheets for healthcare professionals and recipients of the product;
and a discussion of the feasibility of providing this information in an emergency (a sample of instructions for use for an EUA diagnostic panel for the coronavirus is available on FDA’s website)
Information to support an extension of a label’s expiration date, if sought
Any right of reference (a right of reference means “the authority to rely upon, and otherwise use, data submitted from reports of an investigation or data previously submitted to FDA in support of an application, including the ability to make available the underlying raw data for FDA audit”)
~Zorro, Y@h00 RLFTF finance conversations
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-medical-products-and-related-authorities
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM